Breaking News, Collaborations & Alliances

Tekmira Receives Alnylam Milestone

Initiates Phase III LNP-Enabled Patisiran trial

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Tekmira Pharmaceuticals has received a $5 million milestone from Alnylam Pharmaceuticals for the initiation of a Phase III Patisiran trial. Patisiran, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR), is enabled by Tekmira’s lipid nanoparticle (LNP) technology. Tekmira is also entitled to ongoing royalties related to product commercialization.   “We are proud that our proprietary LNP delivery technology is enabling the most advanc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters